
IMRN
Immuron Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.740
Open
1.650
VWAP
--
Vol
67.58K
Mkt Cap
445.25M
Low
1.6306
Amount
--
EV/EBITDA(TTM)
--
Total Shares
5.69M
EV
9.43M
EV/OCF(TTM)
--
P/S(TTM)
2.23
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Show More
Valuation Metrics
The current forward P/E ratio for Immuron Ltd (IMRN.O) is -84.80, compared to its 5-year average forward P/E of -13.23. For a more detailed relative valuation and DCF analysis to assess Immuron Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-13.23
Current PE
-84.80
Overvalued PE
18.16
Undervalued PE
-44.62
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
4.51
Current PS
1.78
Overvalued PS
8.34
Undervalued PS
0.68
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IMRN News & Events
Events Timeline
2025-07-17 (ET)
2025-07-17
06:04:31
Immuron says FY25 global sales exceed projection, up 49% over prior year

2025-03-05 (ET)
2025-03-05
06:03:06
Immuron partners with Calmino to distribute ProIBS in Australia, New Zealand

2025-01-17 (ET)
2025-01-17
05:09:23
Immuron reports strong sales growth of Travelan

Sign Up For More Events
Sign Up For More Events
News
9.5
07-18BenzingaWhy Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
9.5
07-17NewsfilterImmuron - FY25 global sales exceed projection, up 49% on prior year
7.5
04-11SeekingAlphaImmuron exceeds AUD$5 million in sales in a fiscal year
Sign Up For More News
People Also Watch

MMA
Mixed Martial Arts Group Ltd
1.020
USD
-11.30%

AEON
Aeon Biopharma Inc
0.778
USD
-1.39%

HTOO
Fusion Fuel Green PLC
6.130
USD
+2.51%

HWH
HWH International Inc
1.960
USD
+36.11%

CNFR
Conifer Holdings Inc
0.897
USD
-5.18%

LYRA
Lyra Therapeutics Inc
7.260
USD
-6.92%

CISO
CISO Global Inc
1.040
USD
0.00%

JBDI
JBDI Holdings Ltd
0.990
USD
+4.21%

MEGL
Magic Empire Global Ltd
1.450
USD
-17.38%

TXMD
TherapeuticsMD Inc
1.160
USD
-0.85%
FAQ

What is Immuron Ltd (IMRN) stock price today?
The current price of IMRN is 1.66 USD — it has decreased -0.6 % in the last trading day.

What is Immuron Ltd (IMRN)'s business?

What is the price predicton of IMRN Stock?

What is Immuron Ltd (IMRN)'s revenue for the last quarter?

What is Immuron Ltd (IMRN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Immuron Ltd (IMRN)'s fundamentals?

How many employees does Immuron Ltd (IMRN). have?
